Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0012833 (dizziness)
 9,689 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Tiapamil (T), a calcium antagonist, was studied in hypertensive patients by 1) automatic monitor of blood pressure (AMBP), and 2) cuff and stethoscope clinic blood pressure (CBP). Systolic (SBP), diastolic (DBP) pressures and heart rate were measured. Patients (n = 58) received four weeks of placebos given twice daily. Baseline 24 h AMBP (wk 4), 147 +/- 18 (SBP) and 91 +/- 8 (DBP) mmHg; and CBP (wk 3 and 4), 152 +/- 16 (SBP) and 102 +/- 9 (DBP) were established. Then, patients received double-blinded therapy (wk 5-10) of twice daily tablets of placebo (n = 9); Level I T, 150-300 mg (n = 24); or Level II T, 450-600 mg (n = 25): i.e. 0 to 1,200 mg T/d. Significant responses, measured by AMBP (wk 10), were noted only at Level II T: SBP (-10.5 +/- 12.4) and DBP (-5.6 +/- 7.8) mmHg. However, CBP (wk 9 and 10) responded at Level I T (SBP, -7.7 +/- 12.4/DBP, -5.8 +/- 6.4) and Level II T (SBP, -8.8 +/- 9.4/DBP, -9.7 +/- 7.8 mmHg). There was minimal correlation (r = 0.16) of pressure responses to T measured by 24-h AMBP versus CBP methods. Therefore, T effectively lowered SBP and DBP, but individual responses measured by AMBP did not predict those measured by CBP. There was no effect of T on heart rate. Dizziness was noted in 12 percent of patients on T.
 ...
PMID:Antihypertensive effect of tiapamil from ambulatory and clinic methods. 202 64

Tiapamil is an investigational calcium-channel antagonist that is chemically related to verapamil. The antihypertensive efficacies of tiapamil and hydrochlorothiazide (HCTZ) were compared in a randomized double-blind trial. Thirty patients, age 44 to 80 years, with mild to moderate hypertension (World Health Organization stage I-II) entered and completed the study. Previous therapy, if any, was stopped for at least one week prior to study initiation, and patients received placebo tablets for two weeks. The participants were then given active medication, which was titrated for the next three weeks; HCTZ 25 to 50 mg bid or tiapamil 300 to 600 mg bid was given until supine diastolic blood pressure (BP) was no higher than 90 mm Hg or the ceiling dose was reached. Both drugs caused a significant reduction in systolic as well as in diastolic blood pressure (P less than .01). The reduction was seen in both the supine and erect position. The median decrease in supine systolic blood pressure from baseline to the end of treatment was 20 mm Hg in the tiapamil group and 27 mm Hg in the hydrochlorothiazide group, whereas the median decrease in supine diastolic blood pressure was 14 mm Hg and 18 mm Hg, respectively. The median difference in supine diastolic BP reduction after HCTZ and tiapamil administration was 3.8 mm Hg (not significant). There were no significant changes in heart rate. Dizziness occurred in one patient taking tiapamil and in three receiving HCTZ. One patient receiving HCTZ developed acute arthritis urica.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Tiapamil and hydrochlorothiazide: a double-blind comparison of two antihypertensive agents. 331 1